Image

Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

Recruiting
18 years and younger
All
Phase N/A

Powered by AI

Overview

Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.

Description

BACKGROUND

Automatic post-hospitalization follow-up visits are commonly recommended by hospital-based pediatricians. The intuitive appeal of automatic follow-up visits is that they might decrease hospital readmissions and promote continuity of care. However, automatic follow-up visits result in missed work for parents, missed school for children, and expenses like co-pays and transportation costs. The principal alternative strategy to automatic follow-up is PRN (pro re nata, "as-needed") follow-up, a patient and family-centered approach that empowers parents to monitor their child's symptoms and decide if a follow-up visit is necessary.

OBJECTIVE

Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.

DESIGN

The Follow-up Automatically vs As-Needed Comparison (FAAN-C, or "fancy") trial is a multicenter randomized controlled trial

POPULATION

Children hospitalized for pneumonia, skin and soft tissue infection, acute gastroenteritis, or urinary tract infection will be eligible for enrollment.

EXPERIMENTAL INTERVENTION:

Randomization to a recommendation for PRN post-hospitalization follow-up

CONTROL INTERVENTION:

Randomization to a recommendation for automatic post-hospitalization follow-up

OUTCOMES

The primary outcome is hospital readmission within 14 days of discharge. Secondary outcomes are medical interventions and child health-related quality of life. Exploratory outcomes are cost burden, child time, parent time, symptom duration, total additional ambulatory visits, non-primary care ambulatory visits, parent self-efficacy, parent anxiety, satisfaction with care, telephone and electronic communications with medical providers, well-child visits, immunizations, usual place of medical care, and medical interventions related to the index infection. Safety outcomes are medical errors and hospital readmissions related to the index infection.

TRIAL SIZE:

A total of 2,674 patients (1,337 patients in each group) will be randomized, providing 90% power to demonstrate non-inferiority of a recommendation for PRN follow-up compared to a recommendation for automatic follow-up.

Eligibility

Inclusion Criteria:

  • Age <18 years at the time of randomization
  • Hospitalization due to a primary diagnosis of pneumonia, skin and soft tissue infection, acute gastroenteritis, or urinary tract infection.
  • Parent speaks English or Spanish.

Exclusion Criteria:

  • Presence of a comorbid disease that is both chronic and complex
  • Principal disease required surgical intervention (beyond superficial incision and drainage)
  • Immunodeficiency
  • A well-child check-up or post-hospitalization follow-up visit is already scheduled within 7 days of hospital discharge
  • Parent or participant strongly prefers PRN or automatic follow-up
  • A medical provider feels strongly that a post-hospitalization follow-up visit is needed within 7 days of hospital discharge
  • Sibling concurrently hospitalized
  • Unable to identify a clinic where the participant would receive any needed post-hospitalization follow-up
  • Diagnosis of pneumonia complicated by:
    • Receiving a chest tube
  • Diagnosis of urinary tract infection complicated by:
    • History of neurogenic bladder or urologic surgery
    • Renal imaging anticipated within 7 days of hospital discharge
    • Renal abscess
  • Diagnosis of skin and soft tissue infection complicated by:
    • Chronic wound
    • Postoperative infection
    • Predisposition to poor wound healing
    • Discharging with a drain in place
    • Complicated by necrotizing fasciitis or toxic shock syndrome
  • Diagnosis of gastroenteritis complicated by:
    • Hemolytic uremic syndrome

Study details
    Pneumonia
    Urinary Tract Infections
    Soft Tissue Infections
    Gastroenteritis

NCT05471908

University of Utah

16 April 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.